Literature DB >> 24837081

Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma.

Adam J Olszewski1, Eric S Winer2, Jorge J Castillo3.   

Abstract

Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, we investigated the relative benefits of adding rituximab to CHOP chemotherapy in diffuse large B-cell lymphoma (DLBCL) of extranodal origin, and found similar advantage for nodal and extranodal lymphomas. Hazard ratio for overall survival was 0.64 for nodal, and 0.70 for extranodal DLBCL. Hazard ratios for lymphoma-related death were 0.62 and 0.57, respectively. The advantage was largest for DLBCL of the spleen, liver and lung. Conversely, it was not evident for thyroid or testicular lymphomas. Compared with nodal DLBCL, spleen was the only site with significantly better prognosis after R-CHOP.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Comparative effectiveness research; Diffuse large B-cell lymphoma; R-CHOP chemotherapy; Rituximab; SEER program

Mesh：

Substances：

Year:  2014        PMID： 24837081     DOI： 10.1016/j.leukres.2014.04.009

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  8 in total

1.  Primary Urinary Tract Lymphoma: Rare but Aggressive.

Authors:  Konstantinos Lontos; Anastasia Tsagianni; Pavlos Msaouel; Leonard Joseph Appleman; Dimitrios Nasioudis
Journal:  Anticancer Res       Date:  2017-12       Impact factor: 2.480

Review 2.  Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.

Authors:  Thomas A Ollila; Adam J Olszewski
Journal:  Curr Treat Options Oncol       Date:  2018-06-21

3.  TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.

Authors:  Helga D Munch-Petersen; Fazila Asmar; Konstantinos Dimopoulos; Aušrinė Areškevičiūtė; Peter Brown; Mia Seremet Girkov; Anja Pedersen; Lene D Sjö; Steffen Heegaard; Helle Broholm; Lasse S Kristensen; Elisabeth Ralfkiaer; Kirsten Grønbæk
Journal:  Acta Neuropathol Commun       Date:  2016-04-22       Impact factor: 7.801

4.  Trends in Survival of Patients with Primary Gastric Diffuse Large B-Cell Lymphoma: An Analysis of 7051 Cases in the SEER Database.

Authors:  Pan-Pan Liu; Yi Xia; Xi-Wen Bi; Yu Wang; Peng Sun; Hang Yang; Zhi-Ming Li; Wen-Qi Jiang
Journal:  Dis Markers       Date:  2018-10-16       Impact factor: 3.434

Review 5.  Primary Pulmonary B-Cell Lymphoma: A Review and Update.

Authors:  Francesca Sanguedolce; Magda Zanelli; Maurizio Zizzo; Alessandra Bisagni; Alessandra Soriano; Giorgia Cocco; Andrea Palicelli; Giacomo Santandrea; Cecilia Caprera; Matteo Corsi; Giulia Cerrone; Raffaele Sciaccotta; Giovanni Martino; Linda Ricci; Francesco Sollitto; Domenico Loizzi; Stefano Ascani
Journal:  Cancers (Basel)       Date:  2021-01-22       Impact factor: 6.639

6.  Primary diffuse large B-cell lymphoma of orbit: A population-based analysis.

Authors:  Yu-Qing Chen; Zi-Fan Yue; Sai-Nan Chen; Fei Tong; Wei-Hua Yang; Rui-Li Wei
Journal:  Front Med (Lausanne)       Date:  2022-09-15

Review 7.  Primary pulmonary lymphoproliferative neoplasms.

Authors:  Victoria K Tang; Praveen Vijhani; Sujith V Cherian; Manju Ambelil; Rosa M Estrada-Y-Martin
Journal:  Lung India       Date:  2018 May-Jun

8.  Primary Diffuse Large B-Cell Lymphoma of the Urinary Tract: A Population-Based Analysis.

Authors:  Zheng-Huan Liu; Lu-Chen Yang; Pan Song; Kun Fang; Jing Zhou; Zhu-Feng Peng; Qiang Dong
Journal:  Front Oncol       Date:  2021-07-14       Impact factor: 6.244
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.